Citizens’ opinions and experiences related to costs and reimbursements for medications in times of retrenchment: cross-sectional population surveys in 2015 and 2017

Table 4 Perceived fairness: differences in the effects of group across study years

	Agree		Disagree		Don’t know
	AME	se	AME	se	AME	se
AME of group (ref: No Rx use, no eligibility, no diabetes)
a Other Rx users 2015	0.030	0.019	0.088^***	0.019	-0.118^***	0.019
b Other Rx users 2017	0.024	0.018	0.099^***	0.020	-0.122^***	0.020
c Diabetes 2015	0.040	0.027	0.156^***	0.027	-0.196^***	0.023
d Diabetes 2017	0.017	0.024	0.211^***	0.027	-0.229^***	0.023
e Eligibility 2015	0.029	0.023	0.117^***	0.022	-0.146^***	0.021
f Eligibility 2017	0.075^***	0.021	0.118^***	0.023	-0.192^***	0.021
Contrasts
b-a: Other Rx 2017 vs. 2015^a	-0.006	0.026	0.010	0.028	-0.004	0.027
d-c: Diabetes 2017 vs. 2015^a	-0.023	0.036	0.056	0.037	-0.033	0.032
f-e: Eligibility 2017 vs. 2015^a	0.045	0.030	< 0.001	0.031	-0.046	0.029
(d-c)-(b-a) Diab. vs. Other Rx^b	-0.017	0.030	0.045	0.031	-0.029	0.024
(d-c)-(f-e) Diab. vs. Elig.^b	-0.068^*	0.033	0.055	0.034	0.013	0.026
(b-a)-(f-e) Other Rx vs. Elig.^b	-0.051^*	0.023	0.010	0.024	0.042^*	0.019
n	10,801
Pseudo R-square	0.031
AIC	22,465
BIC	22,552

Average marginal effects (AMEs), with standard error (se), of exposure group on the probability of agreeing, disagreeing and being unsure with the statement ‘reimbursements are fair and just’. Contrasts report statistical tests for differences over time in the marginal effects of exposure group vs. reference group(^a), and the other groups vs. each other(^b). Results are based on multinomial logistic regression (interaction: Group X Year). Covariates: Gender, age, NUTS2, survey type. Rx = prescription medicines. ^* p < 0.05, ^** p < 0.01, ^*** p < 0.001

ISSN: 1475-9276